ANSWER: B

Rationale:

This question asked you to apply the established PDP medication-reduction sequence to a patient whose regimen contains identifiable psychotogenic agents that have not yet been addressed. The first step in managing PD psychosis is always a systematic review and reduction of the existing medication burden before adding any antipsychotic drug. In Mr. D.K.'s case, two agents are clear first targets: benztropine, a tertiary amine anticholinergic that crosses the blood-brain barrier and causes psychosis through central muscarinic blockade; and amantadine, which promotes hallucinations through its NMDA glutamate receptor antagonism and indirect dopaminergic properties. Both should be tapered and discontinued before any antipsychotic is considered. If psychosis persists after removing these agents, the next steps are reduction of the dopamine agonist (pramipexole), then the MAO-B inhibitor (rasagiline), and finally levodopa dose reduction as a last resort.

• Option A: Option A is incorrect because pimavanserin, while FDA-approved for PDP, is not the first step — initiating an antipsychotic before removing the identifiable psychotogenic contributors bypasses the most correctable cause of the psychosis.
• Option C: Option C is incorrect because levodopa is the last agent to be reduced in the PDP sequence, not the first; its motor benefit is critical in the immediate postoperative period, and its reduction before addressing the anticholinergic and amantadine burden is pharmacologically incorrect and clinically unsafe.
• Option D: Option D is incorrect because adding quetiapine without first removing benztropine and amantadine is pharmacologically premature and introduces motor risk and limited efficacy evidence for PDP without addressing the correctable contributors.
• Option E: Option E is incorrect because the PDP medication-reduction sequence is a neurological management decision that does not require a psychiatry consultation before its first step; deferring the straightforward first intervention — removing the psychotogenic agents — would prolong the psychosis unnecessarily.

ANSWER: D

Rationale:

This question asked you to identify the precise mechanism by which pimavanserin treats psychosis without worsening parkinsonism. Pimavanserin is a selective inverse agonist at serotonin 5-HT2A and 5-HT2C receptors — it reduces the constitutive activity of these receptors below their baseline level rather than simply blocking ligand binding. Critically, pimavanserin has no binding affinity at dopamine receptors of any subtype. This is the pharmacological basis for its unique safety profile in PD: because it does not occupy D2 receptors in the nigrostriatal pathway, it cannot interfere with the dopaminergic motor therapy that controls Mr. D.K.'s motor symptoms. All conventional antipsychotics — and most atypical antipsychotics — produce their antipsychotic effects at least partly through D2 receptor blockade, which in PD patients directly antagonizes the therapeutic mechanism.

• Option A: Option A is incorrect because pimavanserin does not block dopamine D3 receptors; it has no dopamine receptor binding affinity at any subtype, and the selective mesolimbic D3 blockade described is a theoretical framework applied to some atypical antipsychotics, not to pimavanserin.
• Option B: Option B is incorrect because pimavanserin is not a D2 partial agonist; partial D2 agonism describes aripiprazole's mechanism, not pimavanserin's; pimavanserin has zero D2 receptor binding.
• Option C: Option C is incorrect because pimavanserin does not inhibit serotonin reuptake; serotonin reuptake inhibition is the mechanism of SSRIs and SNRIs, not of 5-HT2A inverse agonists; and reducing psychosis through indirect serotonin-mediated suppression of dopamine release is not how pimavanserin works.
• Option E: Option E is incorrect because pimavanserin does not act through histamine H1 receptor blockade; histaminergic blockade describes the sedating properties of quetiapine and other antipsychotics, not pimavanserin's mechanism.

ANSWER: A

Rationale:

This question asked you to identify the cardiac safety assessment required before pimavanserin initiation and explain its pharmacological basis. Pimavanserin prolongs the QTc interval through blockade of the hERG (human ether-à-go-go related gene) potassium channel, which carries the rapid delayed rectifier current (IKr) responsible for cardiac repolarization. Prolongation of this channel increases the QTc interval and elevates the risk of torsades de pointes, a potentially fatal ventricular arrhythmia. An 18-month-old electrocardiogram is not an adequate baseline — a current measurement is required to assess Mr. D.K.'s present QTc before adding a drug known to prolong it. His prior QTc of 448 ms is within the upper normal range, and any further prolongation from pimavanserin warrants monitoring.

• Option B: Option B is incorrect because pimavanserin is primarily metabolized by CYP3A4, but the required pre-initiation assessment is cardiac (QTc measurement), not hepatic; liver function panels are not part of pimavanserin's standard pre-initiation protocol.
• Option C: Option C is incorrect because mandatory CBC monitoring with REMS requirements for agranulocytosis applies to clozapine, not to pimavanserin; pimavanserin has no hematological toxicity or REMS monitoring requirement.
• Option D: Option D is incorrect because while pimavanserin does require caution in severe renal impairment, the required pre-initiation assessment is the electrocardiogram for QTc measurement, not a renal function panel; and dose reduction at creatinine clearance below 50 mL/min as described is not the primary safety concern framing the pre-initiation assessment.
• Option E: Option E is incorrect because pimavanserin does affect cardiac electrophysiology through hERG channel blockade producing QTc prolongation; dismissing the need for a current electrocardiogram on the grounds that its serotonin receptor mechanism is cardioelectrophysiologically neutral is incorrect.

ANSWER: C

Rationale:

This question asked you to identify the primary contraindication to haloperidol in PD and select the safest approach to acute behavioral management. Haloperidol is a first-generation antipsychotic with extremely high dopamine D2 receptor binding affinity. In a patient with Parkinson's disease, where motor symptom control depends entirely on dopaminergic signaling in the nigrostriatal pathway, central D2 receptor blockade directly antagonizes this therapy and can cause severe, acute worsening of rigidity, bradykinesia, and postural instability — potentially rendering the patient unable to swallow or protect his airway. For acute agitation in a PD patient, low-dose benzodiazepines (lorazepam) provide behavioral control through GABAergic sedation without any dopaminergic mechanism, making them pharmacologically safer than any D2-blocking agent. The existing pimavanserin therapy should be continued and the underlying cause of the acute agitation — pain, urinary retention, delirium from medication changes, or worsening psychosis — assessed and addressed.

• Option A: Option A is incorrect because haloperidol does not inhibit aromatic L-amino acid decarboxylase; its mechanism is D2 receptor blockade, not enzyme inhibition; and while lorazepam is pharmacologically reasonable for acute agitation, the rationale offered is incorrect.
• Option B: Option B is incorrect because haloperidol's primary contraindication in PD is its D2 blockade causing motor worsening, not its anticholinergic properties causing urinary retention; haloperidol has relatively modest anticholinergic effects compared to low-potency antipsychotics; and pimavanserin has no anticholinergic mechanism.
• Option D: Option D is incorrect because haloperidol does not act at 5-HT2A receptors in a way that produces additive blockade with pimavanserin causing serotonin depletion; serotonin depletion syndrome is not a recognized clinical entity from 5-HT2A receptor blockade; and quetiapine 200 mg IM is not an available or appropriate formulation for acute behavioral management.
• Option E: Option E is incorrect because while QTc prolongation is a genuine concern with haloperidol and is additive with pimavanserin, it is not the primary contraindication — the D2-mediated motor worsening is the defining contraindication in PD; and propofol infusion is not a practical or appropriate outpatient-ward intervention for acute agitation.

ANSWER: E

Rationale:

This question asked you to identify the correct mechanism by which fludrocortisone raises blood pressure in neurogenic OH. Fludrocortisone is a synthetic steroid with potent mineralocorticoid activity and minimal glucocorticoid effect at the doses used for OH (0.1–0.2 mg daily). It acts on mineralocorticoid receptors in the principal cells of the renal collecting duct, mimicking the action of endogenous aldosterone: it promotes sodium reabsorption from the tubular fluid in exchange for potassium secretion, and the retained sodium obligates water reabsorption, expanding circulating plasma volume. This volume expansion raises blood pressure through increased cardiac preload and cardiac output. Unlike direct vasopressors, fludrocortisone does not act on adrenergic receptors and does not cause targeted vasoconstriction — its benefit is non-specific volume expansion.

• Option A: Option A is incorrect because the description of a catecholamine precursor converted to norepinephrine by AADC describes droxidopa, not fludrocortisone; fludrocortisone is a steroid hormone acting on nuclear mineralocorticoid receptors, not an amino acid prodrug.
• Option B: Option B is incorrect because peripheral alpha-1 adrenergic receptor agonism describes the mechanism of midodrine's active metabolite desglymidodrine; fludrocortisone does not act on adrenergic receptors.
• Option C: Option C is incorrect because acetylcholinesterase inhibition describes the mechanism of agents like pyridostigmine, which has modest benefit in neurogenic OH through enhanced ganglionic transmission; fludrocortisone does not inhibit acetylcholinesterase and does not act through cholinergic mechanisms.
• Option D: Option D is incorrect because while fludrocortisone is structurally a steroid, at the doses used for OH it exerts predominantly mineralocorticoid rather than glucocorticoid effects; anti-inflammatory vascular mechanisms are not the pharmacological basis for its blood pressure-raising effect.

ANSWER: B

Rationale:

This question asked you to apply fludrocortisone's mechanism to a patient with a specific cardiac comorbidity that makes its pharmacological consequence dangerous. Fludrocortisone expands circulating plasma volume through mineralocorticoid-mediated sodium and water retention in the kidney. In patients with intact cardiac function, this volume expansion is tolerated and therapeutically useful for raising standing blood pressure. In Mrs. R.L., who has HFrEF with an ejection fraction of 38% and is already on optimized guideline-directed therapy, her ventricle is operating near the flat portion of its Frank-Starling curve — additional preload increases left ventricular end-diastolic pressure without generating proportionally more cardiac output, instead raising pulmonary venous pressure and driving fluid into the alveolar spaces. The result is acute decompensated heart failure, which is precisely the complication that her carvedilol and lisinopril are designed to prevent.

• Option A: Option A is incorrect because fludrocortisone does not competitively interact with ACE inhibitors at the pharmacological level in the manner described; ACE inhibitors reduce angiotensin II-driven aldosterone secretion, and fludrocortisone replaces the aldosterone action directly at the mineralocorticoid receptor — these are parallel rather than competing mechanisms, and severe hyponatremia is not the primary concern.
• Option C: Option C is incorrect because while high-dose, long-term mineralocorticoid excess can contribute to cardiac fibrosis, this is not the acute pharmacological concern at the doses used for neurogenic OH; the immediate danger in this patient is volume-mediated acute decompensation, not chronic myocardial fibrosis.
• Option D: Option D is incorrect because fludrocortisone does not upregulate cardiac beta-1 receptors through mineralocorticoid receptor activation; this interaction is not established pharmacology, and carvedilol's beta-blockade is not reversed by mineralocorticoid activity.
• Option E: Option E is incorrect in its characterization of fludrocortisone as causing potassium retention — fludrocortisone causes potassium excretion (hypokalemia) through sodium-potassium exchange in the collecting duct, not potassium retention; the hyperkalemia concern applies to the combination of ACE inhibitors with potassium-sparing diuretics or potassium supplements, not with mineralocorticoids.

ANSWER: D

Rationale:

This question asked you to apply midodrine's pharmacokinetics to explain a predictable and preventable adverse effect of incorrect dose timing. Midodrine is a prodrug that is converted to desglymidodrine, a direct peripheral alpha-1 adrenergic agonist, by plasma esterases. Desglymidodrine has a half-life of approximately two to three hours, meaning that a dose taken at 8 PM will have pharmacologically meaningful plasma concentrations until approximately midnight or later. During upright posture, the alpha-1-mediated vasoconstriction and increased venous tone are therapeutically beneficial — they counteract the gravitational pooling of blood in the lower extremities that causes orthostatic hypotension. But when Mrs. R.L. lies supine, gravitational pooling is eliminated, venous return to the heart is maximal, and the same vasoconstriction now drives blood pressure to dangerously high levels. The standard prescribing instruction for midodrine is that the last dose of the day should be taken at least four hours before the expected time of lying down — in this case, no later than approximately 4 PM if she goes to bed around 8 PM.

• Option A: Option A is incorrect because midodrine does not accumulate in adipose tissue and release in a delayed pharmacokinetic peak; it is a water-soluble prodrug with predictable short-duration pharmacokinetics; no extended-release formulation exists as a solution to this problem.
• Option B: Option B is incorrect because the nocturnal hypertension is not driven by RAAS activation; it is a direct pharmacodynamic consequence of residual alpha-1 agonism from the late evening midodrine dose during recumbency; RAAS involvement is not the mechanism.
• Option C: Option C is incorrect because carvedilol's beta-blockade does not unmask alpha-1 vasoconstriction from midodrine; beta-2 receptor-mediated vasodilation is a relatively minor component of vascular tone regulation, and carvedilol is an essential component of her HFrEF therapy that should not be discontinued.
• Option E: Option E is incorrect because the nocturnal hypertension is not a baroreceptor reflex response to daytime hypotension; it is a direct pharmacodynamic effect of active desglymidodrine during recumbency; reducing the daytime dose would worsen her orthostatic hypotension without addressing the timing problem.

ANSWER: A

Rationale:

This question asked you to precisely contrast the mechanisms of droxidopa and midodrine. Droxidopa is a synthetic amino acid structurally related to levodopa; it is converted to norepinephrine by aromatic L-amino acid decarboxylase (AADC), the same enzyme that converts levodopa to dopamine. The norepinephrine generated acts on the full range of peripheral adrenergic receptors — alpha-1 causing arteriolar constriction and increased vascular resistance, alpha-2 contributing to venous constriction, and beta-1 increasing heart rate and contractility — raising blood pressure through both vascular and cardiac mechanisms. Midodrine, by contrast, is a prodrug converted to desglymidodrine by plasma esterases; desglymidodrine is a direct, selective agonist at peripheral alpha-1 adrenergic receptors only, producing vasoconstriction without the norepinephrine generation or the broader adrenergic receptor activation of droxidopa. Both are FDA-approved for neurogenic orthostatic hypotension and raise standing blood pressure, but through mechanistically distinct pathways.

• Option B: Option B is incorrect because droxidopa does not act as a direct presynaptic alpha-2 agonist to stimulate endogenous norepinephrine release; it generates norepinephrine through enzymatic conversion and acts on postsynaptic receptors as a consequence of the norepinephrine it produces, not by stimulating sympathetic nerve terminals directly.
• Option C: Option C is incorrect because droxidopa and midodrine do not share an identical mechanism and are not both converted to desglymidodrine by plasma esterases; desglymidodrine is the active metabolite of midodrine only, and droxidopa is converted to norepinephrine by AADC through a completely different enzymatic pathway.
• Option D: Option D is incorrect because droxidopa is not a mineralocorticoid and does not raise blood pressure through plasma volume expansion; that mechanism describes fludrocortisone; droxidopa generates norepinephrine, which raises blood pressure through vasoconstriction and cardiac stimulation, not through fluid retention.
• Option E: Option E is incorrect because droxidopa is not a dopamine D1 receptor agonist; it is converted to norepinephrine, not to dopamine, and does not act through renal dopamine receptors to raise blood pressure through renal vascular mechanisms.

ANSWER: C

Rationale:

This question asked you to apply the principle that melatonin is the preferred pharmacological treatment for RBD in patients with cognitive impairment or elevated fall risk. Clonazepam is the most widely studied pharmacological treatment for RBD and is generally the most efficacious, but it is a benzodiazepine with significant CNS depressant effects — sedation, impaired coordination, and worsening of cognitive function — that are substantially amplified in elderly patients with pre-existing cognitive impairment and PD-related gait instability. In Mr. T.W., whose wife is already concerned about cognitive decline, adding clonazepam carries a meaningful risk of accelerating the cognitive trajectory and increasing his fall risk in a population where falls are already a major source of morbidity. Melatonin 3–12 mg at bedtime provides clinically meaningful reduction in RBD enactment frequency and severity through a mechanism — modulation of circadian timing and sleep-wake transitions — that does not involve CNS depression, carries no anticholinergic burden, and does not worsen cognition or gait.

• Option A: Option A is incorrect because the claim that tolerance to clonazepam's cognitive effects develops within two to four weeks is not pharmacologically reliable in elderly patients with cognitive impairment; cognitive impairment and fall risk from benzodiazepines typically persist and may worsen rather than resolve with continued use, and a safer alternative exists.
• Option B: Option B is incorrect because zolpidem is not an established or appropriate treatment for RBD — it promotes sleep onset through GABA-A receptor modulation but does not address the REM atonia loss that drives enactment behavior, and it carries its own risks of complex sleep behaviors, falls, and cognitive impairment in elderly patients.
• Option D: Option D is incorrect because quetiapine's sedating properties do not specifically treat RBD through suppression of REM sleep — RBD treatment requires addressing the brainstem REM atonia circuitry, not simply reducing REM duration — and quetiapine's D2 blockade adds motor risk in a PD patient.
• Option E: Option E is incorrect because pharmacological options with acceptable cognitive risk profiles do exist for RBD in cognitively impaired patients; melatonin specifically is safe in this context, and dismissing all pharmacotherapy leaves the patient and his wife at continued injury risk from untreated enactment episodes.

ANSWER: A

Rationale:

This question asked you to identify the appropriate antidepressant choice in a PD patient on selegiline and the key interaction consideration that guides prescribing. Venlafaxine XR (a serotonin-norepinephrine reuptake inhibitor) has controlled trial evidence for PD depression from the SIC trial and is a reasonable first-line choice. When combining any serotonergic antidepressant with a selective MAO-B inhibitor such as selegiline, the risk of serotonin syndrome is substantially lower than with non-selective MAOIs — the published clinical experience indicates that MAO-B inhibitor plus SSRI/SNRI combinations are generally well tolerated and serotonin syndrome is rare — but the risk is not zero, so monitoring for serotonin syndrome signs (tremor, diaphoresis, agitation, hyperreflexia, hyperthermia) is clinically warranted, and the SSRI or SNRI should be kept at the lower end of its therapeutic range. Among SSRIs, paroxetine is specifically listed in prescribing information as contraindicated with MAO-B inhibitors because of its particularly potent SERT inhibition and its inhibition of CYP2D6, which metabolizes selegiline, creating both pharmacodynamic and pharmacokinetic interaction risks.

• Option B: Option B is incorrect because paroxetine is specifically contraindicated with MAO-B inhibitors in prescribing information, and its anticholinergic properties are a liability — not a benefit — in a patient with mild cognitive impairment; paroxetine is the wrong choice in this patient on two counts.
• Option C: Option C is incorrect because tricyclic antidepressants such as amitriptyline do inhibit serotonin reuptake, making them not free from serotonin syndrome risk when combined with MAO-B inhibitors; additionally, amitriptyline's potent anticholinergic effects are hazardous in a patient with pre-existing cognitive impairment, where anticholinergic burden accelerates cognitive decline.
• Option D: Option D is incorrect because the absolute prohibition on all serotonergic antidepressants with any MAO inhibition applies to non-selective MAOIs; selective MAO-B inhibitors at therapeutic doses carry substantially lower serotonin syndrome risk, and the combination of SSRIs or SNRIs with selective MAO-B inhibitors, while requiring monitoring, is widely used in clinical practice.
• Option E: Option E is incorrect because it overstates the contraindication to an extent that deprives a symptomatic patient of pharmacological treatment; the absolute prohibition on antidepressants applies to non-selective MAOIs, not to selective MAO-B inhibitors at standard doses.

ANSWER: E

Rationale:

This question asked you to recognize serotonin syndrome from its clinical presentation in the context of a pharmacological combination carrying this specific risk. The diagnostic triad of serotonin syndrome is autonomic instability (diaphoresis, hyperthermia), neuromuscular abnormalities (tremor, clonus, hyperreflexia), and altered mental status (agitation) — all of which are present in Mr. T.W. The pharmacological mechanism is convergent: selegiline reduces monoamine oxidase activity (acting predominantly on MAO-B at standard doses), and venlafaxine XR strongly inhibits serotonin reuptake. Although MAO-B inhibitor plus serotonergic combinations are generally well tolerated and serotonin syndrome is rare, the risk is not zero — rare events do occur, particularly with potent serotonergic agents and individual susceptibility — and when they do, the convergence of these two mechanisms produces synaptic serotonin accumulation at 5-HT1A and 5-HT2A receptors in the central and peripheral nervous system, generating the syndrome. This is precisely the interaction risk that warranted monitoring when the combination was initiated.

• Option A: Option A is incorrect because venlafaxine is not an MAO-A inhibitor; it is a serotonin and norepinephrine reuptake inhibitor; tyramine-mediated hypertensive crisis requires MAO-A inhibition in the gut and liver, which venlafaxine does not provide; and the presenting features with clonus and hyperthermia are more consistent with serotonin syndrome than a pure adrenergic hypertensive crisis.
• Option B: Option B is incorrect because neuroleptic malignant syndrome is caused by dopamine receptor blockade or abrupt dopaminergic withdrawal, not by dopamine reuptake inhibition creating excess; venlafaxine does not block dopamine receptors; and NMS presents with lead-pipe rigidity and markedly elevated creatine kinase, not the clonus and diaphoresis pattern seen here.
• Option C: Option C is incorrect because dopamine dysregulation syndrome is characterized by compulsive, reward-driven medication-seeking behavior and does not present with hyperthermia, diaphoresis, and clonus; venlafaxine does not have clinically meaningful dopaminergic activity.
• Option D: Option D is incorrect because venlafaxine does not inhibit COMT; COMT inhibitors are a specific drug class (entacapone, tolcapone) unrelated to antidepressants; and the syndrome described is serotonergic, not a dopamine-deficiency crisis.

ANSWER: B

Rationale:

This question asked you to identify the correct management of serotonin syndrome in a patient with PD. The cornerstone of serotonin syndrome management is immediate discontinuation of all serotonergic agents contributing to the syndrome — in this case both venlafaxine XR and selegiline. Removing only one agent while continuing the other leaves active serotonergic drive in place and prolongs the syndrome. Benzodiazepines are the first-line pharmacological treatment for the neuromuscular manifestations of serotonin syndrome — they reduce the agitation, clonus, and muscle hyperactivity driven by excess serotonergic activity at 5-HT2A receptors without adding any serotonergic mechanism. Cyproheptadine is a non-selective antihistamine and 5-HT2A antagonist that provides direct pharmacological serotonin receptor blockade and is used in moderate-to-severe cases to accelerate symptom resolution. Supportive care — IV fluids, active cooling for hyperthermia, and cardiac monitoring — addresses the systemic consequences of autonomic instability.

• Option A: Option A is incorrect because haloperidol is contraindicated in PD regardless of the clinical indication; its D2 blockade will cause severe motor worsening, and while it does have some 5-HT2A affinity, it is not the treatment for serotonin syndrome in PD and its motor risks are unacceptable.
• Option C: Option C is incorrect because removing only selegiline while continuing venlafaxine leaves active serotonin reuptake inhibition in place; both agents are contributing to the serotonin accumulation, and both must be discontinued for the syndrome to resolve.
• Option D: Option D is incorrect because dantrolene is the treatment for malignant hyperthermia and is sometimes used in neuroleptic malignant syndrome — not in serotonin syndrome; the mechanism of hyperthermia in serotonin syndrome is increased muscle activity and impaired thermogenesis rather than ryanodine receptor-mediated calcium dysregulation, making dantrolene pharmacologically inappropriate for this syndrome.
• Option E: Option E is incorrect because methylene blue is itself a potent MAO inhibitor that increases synaptic monoamine concentrations — administering it in serotonin syndrome would worsen the very process it is purported to treat; methylene blue is contraindicated in serotonin syndrome and is not an FDA-approved treatment for it.

ANSWER: D

Rationale:

This question asked you to identify the pharmacological antagonism between rivastigmine and the concurrent anticholinergic burden that is preventing any therapeutic benefit. Rivastigmine inhibits acetylcholinesterase, increasing the concentration of acetylcholine at cholinergic synapses in the cortex and hippocampus to partially compensate for the severe cholinergic deficit of PDD. But the three co-prescribed medications — oxybutynin, diphenhydramine, and nortriptyline — all carry substantial Anticholinergic Cognitive Burden scores. Oxybutynin is among the highest-burden anticholinergics in clinical use; diphenhydramine is a first-generation antihistamine with potent central muscarinic blockade; nortriptyline, while the most tolerable TCA for elderly patients, still carries significant anticholinergic activity at muscarinic receptors in the central nervous system. All three drugs compete with the acetylcholine that rivastigmine is trying to preserve — they block the muscarinic receptors at the very synapses where increased acetylcholine should be producing cognitive benefit. The result is pharmacological futility: rivastigmine increases acetylcholine, and the concurrent anticholinergics block it before it can act. Deprescribing these agents — substituting mirabegron for oxybutynin, discontinuing diphenhydramine, and substituting a non-anticholinergic pain agent for nortriptyline — must precede any conclusion that rivastigmine is ineffective.

• Option A: Option A is incorrect because the cholinergic nucleus basalis is not completely destroyed at an MMSE of 17; cholinergic neurons degenerate progressively, and residual cholinergic synapses remain functional targets for cholinesterase inhibition at this stage; rivastigmine has demonstrated benefit across a range of PDD severity levels.
• Option B: Option B is incorrect because concluding that the dose is subtherapeutic before removing the agents that are pharmacologically blocking rivastigmine's mechanism is premature; dose escalation while anticholinergic burden remains unaddressed will not produce cognitive benefit.
• Option C: Option C is incorrect because rivastigmine is not significantly metabolized by CYP2D6; it undergoes cholinesterase-mediated hydrolysis rather than hepatic CYP metabolism, making CYP2D6 inhibition by nortriptyline pharmacokinetically irrelevant for rivastigmine.
• Option E: Option E is incorrect because rivastigmine's evidence base in PDD, established by the EXPRESS trial, included patients across a range of cognitive severity and does not restrict benefit to those with MMSE above 24; this claim is factually incorrect and unjustifiably terminates a potentially effective therapy.

ANSWER: C

Rationale:

This question asked you to select the bladder agent that avoids the specific pharmacological mechanism — anticholinergic muscarinic receptor blockade — responsible for the cognitive harm in this patient. Mirabegron acts as a beta-3 adrenergic receptor agonist on the detrusor muscle of the bladder. Beta-3 receptor activation increases intracellular cyclic AMP in detrusor smooth muscle, promoting relaxation during the filling phase and reducing urgency and frequency. Because mirabegron has no muscarinic receptor activity whatsoever, it carries zero anticholinergic cognitive burden — it cannot block the muscarinic receptors that acetylcholine needs to act on for cholinesterase inhibition to produce cognitive benefit. This makes it the pharmacologically correct choice for bladder management in a patient with PDD on rivastigmine.

• Option A: Option A is incorrect because tolterodine ER is a muscarinic M3 antagonist — it is an anticholinergic agent and does cross the blood-brain barrier to a meaningful degree in elderly patients; while it may have somewhat less CNS burden than oxybutynin, it is not cognitively safe in PDD and would partially recreate the anticholinergic antagonism of rivastigmine.
• Option B: Option B is incorrect because solifenacin is also a muscarinic antagonist (M3 selective) and does carry anticholinergic cognitive burden; M3 selectivity reduces peripheral side effects such as tachycardia but does not eliminate central muscarinic blockade, and solifenacin is not appropriate in a patient with PDD on rivastigmine.
• Option D: Option D is incorrect because hyoscyamine is a tertiary amine anticholinergic alkaloid with high CNS penetration and potent central muscarinic blockade — it is among the worst choices for a patient with PDD and should be strictly avoided.
• Option E: Option E is incorrect because while the transdermal oxybutynin patch does reduce the formation of the highly anticholinergic metabolite N-desethyloxybutynin compared to oral oxybutynin, the parent drug oxybutynin itself also has significant muscarinic blocking activity; the patch reduces but does not eliminate the anticholinergic CNS burden, and the pharmacologically correct solution is to use an agent with no anticholinergic mechanism at all — mirabegron.

ANSWER: B

Rationale:

This question asked you to identify the first-line pharmacological approach for PD-related constipation and the agent used for refractory cases, correctly distinguishing their mechanisms. Macrogol (polyethylene glycol) is an osmotic laxative that retains water in the colonic lumen by osmotic pressure, softening stool and facilitating defecation; it is the standard first-line pharmacological treatment for constipation in PD and is well tolerated without significant drug interactions. For patients whose constipation does not respond adequately to osmotic laxatives, increased fiber, and adequate hydration, prucalopride provides an option through a mechanistically distinct pathway: it is a highly selective 5-HT4 receptor agonist that stimulates enteric neurons in the myenteric plexus to enhance peristaltic activity and accelerates colonic transit. This serotonergic prokinetic mechanism is entirely different from osmotic laxation and addresses the enteric nervous system dysfunction that is part of PD pathology.

• Option A: Option A is incorrect because lactulose is an osmotic laxative that works by a similar mechanism to macrogol but generates significant colonic gas and bloating through bacterial fermentation, making it less preferred than macrogol in PD; and naloxegol is specifically indicated for opioid-induced constipation — Mrs. E.M. is not on opioids, and the primary mechanism of PD constipation is enteric nervous system Lewy body pathology, not opioid peptide-mediated inhibition.
• Option C: Option C is incorrect and potentially dangerous: metoclopramide is a dopamine D2 receptor antagonist that is contraindicated in Parkinson's disease because its central D2 blockade causes severe motor worsening; characterizing its central D2 effects as negligible at low doses is pharmacologically inaccurate and clinically hazardous.
• Option D: Option D is incorrect because senna's anthraquinone mechanism stimulates colonic mucosa directly but does not specifically restore the peristaltic activity lost through Lewy body enteric pathology in the way that 5-HT4 receptor agonism can; senna is not the standard first-line recommendation for PD constipation over macrogol.
• Option E: Option E is incorrect because magnesium hydroxide has no established synergistic interaction with rivastigmine's cholinomimetic mechanism; this pharmacological claim is fabricated and there is no clinical basis for preferring magnesium hydroxide over macrogol in patients on rivastigmine.

ANSWER: E

Rationale:

This question asked you to apply the cognitive safety hierarchy in PDD — specifically the principle that any agent with Anticholinergic Cognitive Burden above zero should be avoided in patients with established dementia — to select among sialorrhea management options. Mrs. E.M. has PDD on rivastigmine, a cholinesterase inhibitor that is already compensating for a severe cholinergic deficit; adding any centrally active anticholinergic agent would directly antagonize rivastigmine's mechanism and risk precipitating another episode of drug-induced cognitive deterioration identical to the one caused by oxybutynin, diphenhydramine, and nortriptyline. The two pharmacologically safe options for sialorrhea in this context are glycopyrrolate and botulinum toxin. Glycopyrrolate is a quaternary ammonium compound whose permanent positive charge prevents it from crossing the blood-brain barrier, allowing peripheral reduction of salivary secretion through muscarinic receptor blockade in the salivary glands without central anticholinergic effects. Botulinum toxin injection into the parotid and submandibular glands blocks acetylcholine release from parasympathetic nerve terminals locally for three to six months, providing effective sialorrhea control with no systemic anticholinergic mechanism.

• Option A: Option A is incorrect because atropine is a tertiary amine alkaloid with excellent CNS penetration; sublingual atropine at any clinically effective dose will produce central muscarinic blockade and worsen cognition in a patient with PDD — it is not a safe option regardless of route.
• Option B: Option B is incorrect because benztropine is a tertiary amine anticholinergic that readily crosses the blood-brain barrier; the claim that low doses produce only peripheral effect without CNS activity is pharmacologically inaccurate — even low doses of centrally penetrant anticholinergics are problematic in PDD.
• Option C: Option C is incorrect because scopolamine is a tertiary alkaloid with high CNS penetration regardless of delivery route; transdermal delivery does not prevent the drug from crossing the blood-brain barrier once absorbed systemically, and scopolamine is among the most potent centrally acting anticholinergics.
• Option D: Option D is incorrect because oxybutynin at any dose crosses the blood-brain barrier and has central anticholinergic effects; the dose reduction from 5 mg to 2.5 mg reduces but does not eliminate the central muscarinic blockade, and after the cognitive deterioration already caused by oxybutynin, reintroducing it at any dose in a patient with PDD on rivastigmine is inappropriate.

ANSWER: A

Rationale:

This question asked you to correctly identify pramipexole's mechanism of sedation and the appropriate management sequence. Pramipexole is a non-ergot dopamine agonist with preferential activity at D3 receptors (and also D2 receptors), and it is among the more sedating dopamine agonists in clinical use. D3 receptors are expressed in limbic and hypothalamic circuits that regulate sleep and arousal, and their stimulation contributes to the sedation and sudden-onset sleep episodes associated with pramipexole. The correct management principle is to address the pharmacological contributor first — by switching to a less sedating dopamine agonist formulation (such as rotigotine transdermal patch, which produces more stable plasma levels) or by reducing the pramipexole dose — before adding a wake-promoting agent such as modafinil. Adding modafinil without first reducing the sedating agonist would mask rather than address the pharmacological cause.

• Option B: Option B is incorrect because pramipexole's sedating effects are mediated through dopamine D2/D3 receptor agonism in arousal circuits, not through alpha-2 adrenergic receptor agonism; alpha-2 agonism in the locus coeruleus describes the mechanism of clonidine and similar agents, not pramipexole.
• Option C: Option C is incorrect because pramipexole does not inhibit CYP3A4; it is not a CYP enzyme inhibitor, and its pharmacokinetics do not involve fatty acid amide endocannabinoid system interactions; this mechanism is pharmacologically fabricated.
• Option D: Option D is incorrect because pramipexole does contribute meaningfully to EDS in PD; dismissing this well-documented pharmacological effect and proceeding directly to modafinil without addressing the contributing agent is not the correct management sequence.
• Option E: Option E is incorrect because pramipexole's sedating mechanism is not mediated through D4 receptor inhibition in the prefrontal cortex; D4 receptors play a role in prefrontal cognition but this is not pramipexole's EDS mechanism; and cabergoline is an ergot dopamine agonist with a cardiac valvulopathy risk that has largely removed it from clinical use.

ANSWER: D

Rationale:

This question asked you to integrate the pharmacological management of EDS with the patient safety obligation arising from a documented sudden-onset sleep episode while driving. A near-miss driving incident from uncontrolled EDS is not a minor clinical footnote — it is an immediate safety emergency. The patient must be instructed unambiguously to stop driving until his EDS is under adequate pharmacological control and a clinician has assessed him as fit to drive. Partial restrictions ("avoid early mornings," "short trips only") are inadequate because sudden-onset sleep episodes in PD are unpredictable in timing and cannot be reliably restricted to specific circumstances. Modafinil 100 mg in the morning is the appropriate pharmacological add-on — it has randomized controlled trial evidence for improving subjective EDS in PD and is the most widely used wake-promoting agent for this indication — but its initiation does not mean driving can resume immediately; clinical reassessment of EDS and driving fitness must precede any return to driving.

• Option A: Option A is incorrect because a partial driving restriction after a documented near-miss is inadequate; time-of-day restrictions do not address the unpredictable nature of sudden-onset sleep in PD, and starting modafinil at 200 mg exceeds the standard initial dose without justification.
• Option B: Option B is incorrect because the clinical evidence does not establish that modafinil and caffeine in combination eliminate sudden-onset sleep episodes; advising a patient with active and dangerous EDS to drive with caffeine augmentation is clinically unsafe and potentially negligent.
• Option C: Option C is incorrect because a near-miss driving episode is not a transient pharmacokinetic phenomenon to be awaited through and cannot be dismissed; rotigotine steady-state plasma concentrations are typically achieved within two to three days, not the two weeks described, and the event requires immediate action.
• Option E: Option E is incorrect because the clinical priority is patient and public safety, not disability accommodation logistics; modafinil does not achieve full therapeutic effect for EDS within 24 hours in a reliable manner that justifies immediate driving resumption, and the legal framing of this response sidesteps the physician's primary obligation to prevent harm.

ANSWER: C

Rationale:

This question asked you to apply the PD pain classification framework — specifically the principle that the first clinical question is always whether the pain is fluctuation-related — to correctly identify and treat off-period dystonic pain. The clinical pattern is definitive: severe foot cramping occurring 40 minutes before the first morning levodopa dose (when overnight plasma concentrations have fallen to sub-therapeutic levels) and resolving 30 minutes after the dose is taken (when dopaminergic coverage is restored). This is the textbook presentation of off-period dystonic pain — a predictable manifestation of dopamine deficiency in the motor circuits controlling the foot and ankle. The correct primary pharmacological intervention is not an analgesic but optimization of the levodopa regimen: adding a bedtime controlled-release levodopa dose to extend nocturnal coverage, shortening the morning dosing interval, or adding a COMT inhibitor to prolong the duration of each dose's effect. Botulinum toxin injection into the affected foot and calf muscles (typically tibialis posterior and gastrocnemius) provides targeted relief by reducing the dystonic contraction independently of the dopaminergic state and is a valuable complementary intervention. Pregabalin and other non-dopaminergic analgesics are reserved for PD pain that persists across both on and off motor states — indicating a mechanism independent of dopaminergic fluctuation.

• Option A: Option A is incorrect because the pain's time-locked dose-cycle relationship is the defining feature of dopaminergically responsive off-period pain; small-fiber neuropathy does not characteristically resolve within 30 minutes of taking levodopa, making that diagnosis inconsistent with the clinical pattern.
• Option B: Option B is incorrect because structural pathology such as Morton's neuroma or plantar fasciitis does not characteristically resolve with levodopa administration; the pharmacological dose-response relationship is pathognomonic for dopaminergically responsive pain and makes structural imaging a lower priority.
• Option D: Option D is incorrect because PD pain is not uniformly driven by central sensitization requiring alpha-2-delta ligands; the pain classification framework specifically identifies off-period pain as dopaminergically responsive, requiring levodopa optimization rather than gabapentinoid therapy.
• Option E: Option E is incorrect because the presenting features are not characteristic of restless legs syndrome — RLS involves an urge to move the legs with discomfort that is worse at rest and better with movement, not a cramping dystonic posture that requires massage and resolves pharmacologically with levodopa; and Mr. P.G. is already on a dopamine agonist through his rotigotine patch.

ANSWER: B

Rationale:

This question asked you to distinguish between two commonly confused non-motor symptoms of PD — central fatigue and excessive daytime sleepiness — and identify the pharmacological approach to fatigue. EDS is the tendency to fall asleep involuntarily, measured by instruments such as the Epworth Sleepiness Scale, and is addressed by modafinil and management of the sedating medication burden. Central fatigue is fundamentally different: it is a pervasive lack of energy and mental vitality that is present even when the patient is fully awake, not drowsy, and in good motor control — it cannot be overcome simply by arousal or stimulation. In PD, central fatigue arises from neurodegeneration of circuits governing motivation, energy regulation, and arousal that are distinct from the orexin system targeted by modafinil. Central fatigue is characteristically poorly responsive to standard antidepressants, even when depression co-exists and has been treated, which distinguishes it from the fatigue of depression. Methylphenidate at low doses has been evaluated in randomized trials for PD fatigue with some evidence of benefit, thought to reflect its dopaminergic and noradrenergic stimulant effects on motivational and arousal circuits. Modafinil may additionally benefit fatigue in some patients.

• Option A: Option A is incorrect because central fatigue and EDS are clinically distinct phenomena with different underlying mechanisms and different responses to treatment; equating them and escalating modafinil misses the diagnostic distinction that the question is designed to test.
• Option C: Option C is incorrect because central fatigue in PD, while it coexists with depression in many patients, is not pharmacologically equivalent to depressive anhedonia and does not reliably respond to SSRIs; clinical trials of SSRIs in PD have not consistently demonstrated benefit for the fatigue symptom independent of depression treatment.
• Option D: Option D is incorrect because while adenosine A2A receptor interactions in PD have been a research interest — particularly for neuroprotection — the mechanism described for central fatigue causation and the claim that high-dose caffeine is superior to modafinil for this indication are not supported by clinical trial evidence and overstate the pharmacological basis.
• Option E: Option E is incorrect because pharmacological options with evidence for PD fatigue do exist — specifically methylphenidate — and characterizing the symptom as universally untreatable denies the patient access to a potentially beneficial intervention.

ANSWER: E

Rationale:

This question asked you to recognize acute akinesia from dopaminergic withdrawal — one of the most dangerous and preventable complications in hospitalized PD patients — and identify the immediate required intervention. In advanced PD, the brain's dopaminergic circuits are profoundly depleted and entirely dependent on continuous pharmacological replacement; even a few hours without levodopa can produce severe akinesia, rigidity, and loss of swallowing automaticity. The "postoperative ileus — not tolerating medications" documentation reflects a dangerous misunderstanding: the NPO protocol designed to protect the surgical airway from aspiration of stomach contents must never be applied to antiparkinson medications in a patient with PD, because the consequences of withholding them — including profound dysphagia and aspiration of secretions from the rigid, akinetic state — are far more dangerous than the risk of the medications themselves. The immediate intervention is to administer carbidopa/levodopa via nasogastric tube if the patient cannot swallow, and to confirm that the rotigotine patch is still in place providing transdermal dopaminergic coverage. If nasogastric access is not immediately available, subcutaneous apomorphine is an alternative for acute dopaminergic rescue.

• Option A: Option A is incorrect because malignant hyperthermia is a life-threatening reaction to volatile anesthetic agents or succinylcholine characterized by extremely rapid hyperthermia, severe rigidity, and metabolic acidosis that typically presents intraoperatively or within minutes to hours of anesthetic exposure — not six hours postoperatively as a delayed finding in a patient who tolerated the surgery; the clinical pattern here is dopaminergic withdrawal.
• Option B: Option B is incorrect because surgical site infection presenting with systemic inflammatory response typically develops 24 to 72 hours postoperatively, not within four to six hours; and the profound rigidity and mutism described are not features of early wound infection — they are features of dopaminergic deficiency.
• Option C: Option C is incorrect because opioid sedation causes drowsiness and respiratory depression, not the severe rigidity and near-mutism described; and postoperative pain-mediated muscle guarding is not rigid enough to prevent turning in bed without assistance — the degree of motor impairment described requires a specific explanation beyond pain.
• Option D: Option D is incorrect because the clinical picture — profound rigidity, near-mutism, low-grade fever developing over four to six hours in the context of withheld dopaminergic medications — is not consistent with subtle motor seizures; seizures would not produce the progressive rigid akinetic state described, and levetiracetam loading is not the appropriate first intervention in this context.

ANSWER: A

Rationale:

This question asked you to identify the pharmacological basis for metoclopramide's contraindication in PD and specify the safe alternatives. Metoclopramide is a dopamine D2 receptor antagonist that achieves meaningful CNS penetration at standard doses, blocking D2 receptors in the basal ganglia and directly antagonizing the dopaminergic motor therapy that is the pharmacological foundation of Mr. C.N.'s PD management. Even a single dose can precipitate clinically significant acute motor worsening in a patient with advanced disease. Ondansetron exerts its antiemetic effect by blocking serotonin 5-HT3 receptors at the chemoreceptor trigger zone and vagal afferents, with no dopamine receptor activity — it is pharmacologically safe in PD. Domperidone blocks D2 receptors in the gut and chemoreceptor trigger zone but does not cross the blood-brain barrier at standard antiemetic doses, providing peripheral antiemetic benefit without the central motor consequences.

• Option B: Option B is incorrect because prochlorperazine is a phenothiazine antipsychotic with potent central D2 blockade and is contraindicated in PD for the same reason as metoclopramide; levodopa's competitive agonism does not prevent clinically meaningful D2 blockade from high-affinity antagonists like prochlorperazine; and metoclopramide's contraindication in PD is its D2 blockade, not COMT inhibition.
• Option C: Option C is incorrect because metoclopramide's antiemetic mechanism at any antiemetic dose includes meaningful D2 receptor blockade — there is no dose threshold below which metoclopramide acts exclusively through 5-HT4 agonism; this threshold does not exist pharmacologically, and even low doses carry D2 blockade risk in advanced PD.
• Option D: Option D is incorrect because haloperidol is a high-potency D2 blocker that is strictly contraindicated in PD; levodopa's competitive agonism does not prevent D2 blockade by high-affinity full antagonists at antiemetic doses — the affinity of haloperidol for D2 receptors far exceeds its displacement by endogenous or exogenous dopamine at physiological concentrations.
• Option E: Option E is incorrect because safe antiemetic options — specifically ondansetron — do exist in PD patients on rasagiline; ondansetron has no dopamine receptor activity and no MAO interaction, making it both safe and effective.

ANSWER: D

Rationale:

This question asked you to apply the principle of pharmacological triage — addressing the most immediately correctable causes before proceeding to structural investigation — in a patient with known and documented medication administration errors. A head CT is not urgently required before addressing an obvious pharmacological explanation: two late levodopa doses in an advanced PD patient on every-three-hour dosing, combined with a withheld rasagiline, represent a meaningful reduction in dopaminergic coverage that can produce delirium and confusion in addition to motor deterioration. The immediate clinical priority is to ensure correct and timely administration of all antiparkinson medications, perform a full medication reconciliation to identify any additional inadvertent omissions, and reassess the patient's neurological status after pharmacological stabilization. CT imaging can be ordered if the confusion persists or if clinical findings suggest focal neurological pathology. The hospital environment creates multiple hazards for PD patients — delayed medication administration, incorrect NPO application, and unfamiliar care teams — and vigilance about the medication schedule is the clinician's primary inpatient responsibility in this population.

• Option A: Option A is incorrect because while intracranial hemorrhage must eventually be excluded if confusion persists, mandatory CT as the first step before assessing and correcting documented medication administration errors represents a failure of pharmacological triage; the correctable cause should be addressed first.
• Option B: Option B is incorrect because propofol infusion syndrome is a rare complication of prolonged high-dose propofol infusion (typically in ICU settings lasting more than 48 hours), not a consequence of standard anesthetic propofol use for a hernia repair; the clinical picture described is not consistent with this syndrome.
• Option C: Option C is incorrect because rasagiline does not cause a withdrawal syndrome characterized by acute confusion and agitation when discontinued abruptly; MAO-B inhibitors do not produce the type of physiological dependence that generates an acute withdrawal state upon discontinuation, and prioritizing rasagiline restart over correcting levodopa dosing errors misrepresents the pharmacological urgency.
• Option E: Option E is incorrect because rasagiline's MAO-B inhibition does not cause serotonin excess from dietary restriction during NPO status; the tyramine mechanism in MAO inhibition involves MAO-A in the gut wall metabolizing dietary tyramine — dietary restriction during NPO does not cause serotonin accumulation; this mechanism is pharmacologically fabricated.

ANSWER: C

Rationale:

This question asked you to navigate the antipsychotic selection decision in PD — identifying the safest available options and the pharmacological basis for their relative safety compared to contraindicated alternatives. In PD, all antipsychotics with significant D2 receptor blockade — including all first-generation agents (haloperidol, chlorpromazine) and several atypical agents (risperidone, olanzapine) — are contraindicated because central D2 blockade directly antagonizes dopaminergic motor therapy and can precipitate acute severe motor worsening. The agents with the most acceptable risk profile in PD are quetiapine at very low doses (12.5–25 mg), where D2 occupancy is substantially lower than at antipsychotic doses, and pimavanserin, which has no D2 binding whatsoever and is the only FDA-approved agent for PD psychosis specifically. Neither agent is perfectly without risk or guaranteed effective — quetiapine's limited PDP efficacy data and pimavanserin's QTc concern are genuine trade-offs — but both are pharmacologically far superior to D2-blocking agents in this specific context. In the acute inpatient setting, the primary intervention remains ensuring correct antiparkinson medication timing and removing any psychotogenic contributors, with antipsychotic pharmacotherapy reserved for refractory cases.

• Option A: Option A is incorrect because haloperidol is strictly contraindicated in Parkinson's disease at any dose — its high D2 receptor affinity causes severe acute motor worsening that can be irreversible; the claim that low-dose high-affinity D2 blockade paradoxically stabilizes signaling rather than blocking it is pharmacologically fabricated.
• Option B: Option B is incorrect because olanzapine causes unacceptable motor worsening in PD patients in controlled trials; it does not have mesolimbic D3 selectivity in a way that spares nigrostriatal motor circuits, and the endorsement of olanzapine below 5 mg as safe in PD contradicts the established clinical evidence.
• Option D: Option D is incorrect because risperidone has a pharmacological profile that includes substantial D2 blockade and causes clinically significant motor worsening in PD patients; its 5-HT2A to D2 ratio is not equivalent to clozapine's extremely low D2 occupancy profile, and risperidone is not considered safe in PD — it is among the agents that movement disorder specialists most consistently identify as contraindicated.
• Option E: Option E is incorrect because pharmacological options with acceptable risk profiles in PD psychosis — quetiapine at very low doses and pimavanserin — do exist; categorically refusing all antipsychotics when persistent distressing psychotic symptoms require management and the pharmacologically appropriate options are available is neither clinically correct nor in the patient's best interest.